The company (Eli Lilly) submitted evidence to NICE for mirikizumab, in the treatment of people with moderately to severely active ulcerative colitis (UC), to be considered under NICE’s proportionate approach to technology appraisals (PATT) streamlined cost-comparison process. This report is the external assessment group’s (EAG’s) critique of the company’s submission (CS). It identifies the strengths and weaknesses of the CS
Background: Bowel urgency reduces ulcerative colitis patients' quality of life. Mirikizumab, a p19-d...
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We inv...
Aims: To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs ...
The company (Eli Lilly) submitted evidence to NICE for mirikizumab, in the treatment of people with ...
This report is a critique of the company’s submission (CS) to NICE from Janssen-Cilag on the clinica...
This report is a critique of the company’s submission (CS) to NICE from Pfizer on the clinical effec...
This report was commissioned by the NIHR Systematic Reviews Programme as project number 13/54/43Exec...
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgot...
As part of its single technology appraisal (STA) process, the National Institute for Health and Care...
Biological agents are emerging treatment options for the management of ulcerative colitis (UC). Purp...
The management of moderate to severe ulcerative colitis has undergone significant changes over the p...
As part of the single technology appraisal (STA) process, the National Institute for Health and Care...
As part of the single technology appraisal (STA) process, the National Institute for Health and Care...
BACKGROUND & AIMS: In 2016, the European Medicines Agency (EMA) and the US Food and Drug Administrat...
Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conf...
Background: Bowel urgency reduces ulcerative colitis patients' quality of life. Mirikizumab, a p19-d...
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We inv...
Aims: To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs ...
The company (Eli Lilly) submitted evidence to NICE for mirikizumab, in the treatment of people with ...
This report is a critique of the company’s submission (CS) to NICE from Janssen-Cilag on the clinica...
This report is a critique of the company’s submission (CS) to NICE from Pfizer on the clinical effec...
This report was commissioned by the NIHR Systematic Reviews Programme as project number 13/54/43Exec...
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgot...
As part of its single technology appraisal (STA) process, the National Institute for Health and Care...
Biological agents are emerging treatment options for the management of ulcerative colitis (UC). Purp...
The management of moderate to severe ulcerative colitis has undergone significant changes over the p...
As part of the single technology appraisal (STA) process, the National Institute for Health and Care...
As part of the single technology appraisal (STA) process, the National Institute for Health and Care...
BACKGROUND & AIMS: In 2016, the European Medicines Agency (EMA) and the US Food and Drug Administrat...
Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conf...
Background: Bowel urgency reduces ulcerative colitis patients' quality of life. Mirikizumab, a p19-d...
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We inv...
Aims: To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs ...